French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that the US Food and Drug Administration (FDA) has accepted its supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv) under priority review.
The application seeks to expand Tzield's use to children aged one year and older with stage 2 type 1 diabetes to delay progression to stage 3.
The sBLA is supported by interim one-year data from the PETITE-T1D phase 4 study, which evaluates the safety and pharmacokinetics of Tzield in young children. Data were presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes and published in Diabetologia.
Tzield acts by protecting insulin-secreting beta cells, slowing disease progression.
Priority review is granted to therapies that could significantly improve treatment of serious conditions. The FDA target action date for the decision is 29 April 2026.
The safety and efficacy of Tzield in this population have not yet been approved by any regulatory authority.
Sciwind Biosciences reports positive study data on ecnoglutide versus semaglutide
Tandem Diabetes Care receives CE mark for expanded automated insulin delivery indications in Europe
Lupin's Ranluspec (ranibizumab) injection receives US FDA approval
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Samsung Bioepis launches OPUVIZ across Europe for ophthalmic conditions
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada